QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)

SELLAS Life Sciences Group (SLS) Competitors

$1.64
-0.05 (-2.96%)
(As of 06/9/2023 ET)
Compare
Today's Range
$1.64
$1.72
50-Day Range
$1.41
$6.15
52-Week Range
$1.17
$5.58
Volume
134,252 shs
Average Volume
338,169 shs
Market Capitalization
$46.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

SLS vs. NXTC, ASMB, MEIP, ENLV, NRXP, MBIO, CARM, SNSE, NBRV, and ASLN

Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include NextCure (NXTC), Assembly Biosciences (ASMB), MEI Pharma (MEIP), Enlivex Therapeutics (ENLV), NRx Pharmaceuticals (NRXP), Mustang Bio (MBIO), Carisma Therapeutics (CARM), Sensei Biotherapeutics (SNSE), Nabriva Therapeutics (NBRV), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical preparations" industry.

SELLAS Life Sciences Group vs.

SELLAS Life Sciences Group (NASDAQ:SLS) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

SELLAS Life Sciences Group has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, NextCure has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500.

10.7% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 54.7% of NextCure shares are owned by institutional investors. 1.6% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, SELLAS Life Sciences Group and SELLAS Life Sciences Group both had 1 articles in the media. SELLAS Life Sciences Group's average media sentiment score of 1.87 beat NextCure's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Overall Sentiment
SELLAS Life Sciences Group Very Positive
NextCure Neutral

NextCure received 62 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 61.40% of users gave NextCure an outperform vote while only 53.33% of users gave SELLAS Life Sciences Group an outperform vote.

CompanyUnderperformOutperform
SELLAS Life Sciences GroupOutperform Votes
8
53.33%
Underperform Votes
7
46.67%
NextCureOutperform Votes
70
61.40%
Underperform Votes
44
38.60%

NextCure's return on equity of -40.05% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences Group N/A -287.10% -131.74%
NextCure N/A -40.05% -37.54%

SELLAS Life Sciences Group presently has a consensus price target of $7.00, indicating a potential upside of 326.83%. NextCure has a consensus price target of $7.00, indicating a potential upside of 321.69%. Given SELLAS Life Sciences Group's stronger consensus rating and higher possible upside, equities analysts clearly believe SELLAS Life Sciences Group is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
NextCure
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

SELLAS Life Sciences Group has higher earnings, but lower revenue than NextCure. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences Group$1 million46.49-$41.30 million-$1.65-0.99
NextCure$22.38 million2.06-$74.73 million-$2.53-0.66

Summary

NextCure beats SELLAS Life Sciences Group on 9 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLS vs. The Competition

MetricSELLAS Life Sciences GroupPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$46.49M$5.95B$4.59B$6.29B
Dividend YieldN/A2.59%2.27%6.19%
P/E Ratio-0.995.8096.5913.14
Price / Sales46.49333.413,289.3488.76
Price / CashN/A20.9592.19113.59
Price / Book7.134.774.695.30
Net Income-$41.30M$194.45M$118.07M$193.23M
7 Day Performance-4.09%0.41%0.86%1.51%
1 Month Performance-73.33%0.88%1.50%5.17%
1 Year Performance-73.33%17.83%8.60%3.11%

SELLAS Life Sciences Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXTC
NextCure
2.1329 of 5 stars
$1.75
+1.7%
$7.00
+300.0%
-62.3%$48.70M$22.38M-0.6987Positive News
ASMB
Assembly Biosciences
2.5336 of 5 stars
$0.95
-3.1%
$2.17
+128.1%
-47.7%$49.51M$6.25M-0.52102
MEIP
MEI Pharma
2.2888 of 5 stars
$7.23
-1.6%
$40.00
+453.6%
-43.1%$48.12M$40.70M-1.3176
ENLV
Enlivex Therapeutics
2.0432 of 5 stars
$2.63
+1.9%
$15.00
+470.3%
-40.0%$47.90MN/A-1.5650Positive News
Gap Up
NRXP
NRx Pharmaceuticals
2.2761 of 5 stars
$0.70
flat
$3.00
+328.6%
-15.1%$50.09MN/A-1.232News Coverage
Gap Up
MBIO
Mustang Bio
2.108 of 5 stars
$6.21
+19.7%
$43.33
+597.8%
-35.5%$50.67MN/A-0.60102High Trading Volume
CARM
Carisma Therapeutics
2.241 of 5 stars
$4.99
-3.7%
$10.00
+100.4%
N/A$50.80M$40M-1.27N/ANews Coverage
SNSE
Sensei Biotherapeutics
2.0596 of 5 stars
$1.50
+4.9%
N/A-36.6%$46.47MN/A-0.9956News Coverage
NBRV
Nabriva Therapeutics
0 of 5 stars
$1.61
+3.9%
N/A-72.7%$51.54M$36.94M-0.0872
ASLN
ASLAN Pharmaceuticals
1.5895 of 5 stars
$3.72
-4.9%
$16.00
+330.1%
+102.1%$51.89MN/A-0.9118

Related Companies and Tools

This page (NASDAQ:SLS) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -